Eligi
Med
Ensayos clinicos
Suscripcion
Sobre EligiMed
Ensayos Clinicos de Alergia e Inmunologia | EligiMed
Ensayos clinicos
104 ensayos encontrados
Terminado
Fase 3
ClinicalTrials.gov
A 2-treatment Period, Randomized, Placebo-controlled, Multicenter Parallel-group Study to Assess the Safety of QAW039 When Added to Existing Asthma Therapy in GINA Steps 3, 4 and 5 Patients With Uncontrolled Asthma.
INTERVENTIONAL
Inicio: 21 de mar de 2017
ID: NCT03052517
Completado
Fase 3
ClinicalTrials.gov
A Phase III, Randomised, Double Blind, Multicentre, Parallel Group, Non Inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in Human Immunodeficiency Virus 1 Infected Treatment naïve Adults
INTERVENTIONAL
Inicio: 21 de jul de 2016
ID: NCT02831673
Terminado
Fase 2
ClinicalTrials.gov
A Phase 2b Randomized, Active-Controlled, Double-Blind Trial to Investigate Safety, Efficacy, and Dose-response of BMS-955176, Given on a Backbone of Tenofovir/Emtricitabine, in Treatment-Naive HIV-1 Infected Adults
INTERVENTIONAL
Inicio: 12 de may de 2015
ID: NCT02415595
Reclutando
Fase 2
ClinicalTrials.gov
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Participants With Sjögren's
INTERVENTIONAL
Inicio: 23 de abr de 2025
ID: NCT06928142
Reclutando
Fase 3
ClinicalTrials.gov
A Multicenter Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan in Adult Participants With Primary IgA Nephropathy Who Have Completed Study CLNP023X2203 or CLNP023A2301
INTERVENTIONAL
Inicio: 20 de sept de 2021
ID: NCT04557462
Completado
Fase 3
ClinicalTrials.gov
Double-blind, Randomised, Placebo-controlled, Phase III Study Comparing the Efficacy and Safety of Bilastine 20 mg Once Daily and Levocetirizine 5 mg for the Treatment of Chronic Idiopathic Urticaria
INTERVENTIONAL
Inicio: 1 de jul de 2006
ID: NCT00421109
Reclutando
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Double-blind, Study Evaluating Efficacy and Safety of Riliprubart Versus Intravenous Immunoglobulin (IVIg) in Participants With Chronic Inflammatory Demyelinating Polyneuropathy
INTERVENTIONAL
Inicio: 21 de ago de 2024
ID: NCT06290141
Completado
Fase 2
ClinicalTrials.gov
TMC125-TiDP2-C238: A Randomized, Exploratory, Open-label 48-week Trial to Investigate the Pharmacokinetics, Safety, Tolerability and Antiviral Activity of Etravirine (ETR) in Combination With Ritonavir-boosted Atazanavir (ATV/Rtv) and 1 NRTI in Treatment-experienced HIV-1 Infected Subjects
INTERVENTIONAL
Inicio: 1 de ago de 2009
ID: NCT00896051
Completado
Fase 3
ClinicalTrials.gov
Sub-study to the A2M Study to Evaluate the Pharmacokinetics, Tolerability and Efficacy of Cabotegravir and Rilpivirine Long-Acting Injections Following Intramuscular Administration in the Vastus Lateralis Muscle (Thigh) in HIV-infected Adult Participants Who Have Received at Least Three Years of Gluteal Injections in the A2M Study
INTERVENTIONAL
Inicio: 28 de oct de 2021
ID: NCT05896761
Completado
Fase 3
ClinicalTrials.gov
Phase 3 Trial to Investigate the Efficacy, Safety, and Tolerability of Blinatumomab as Consolidation Therapy Versus Conventional Consolidation Chemotherapy in Pediatric Subjects With HR First Relapse B-precursor ALL
INTERVENTIONAL
Inicio: 10 de nov de 2015
ID: NCT02393859
Activo, no recluta
Fase 2
ClinicalTrials.gov
A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants With Melanoma (KEYMAKER-U02): Substudy 02B
INTERVENTIONAL
Inicio: 1 de jul de 2020
ID: NCT04305054
Completado
Fase 4
ClinicalTrials.gov
An Open-Label Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Etravirine (ETR) in Combination With Other Antiretrovirals (ARVs) in Antiretroviral Treatment-Experienced HIV-1 Infected Subjects
INTERVENTIONAL
Inicio: 1 de sept de 2011
ID: NCT01422330
Completado
Fase 3
ClinicalTrials.gov
A Phase 3, Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled Induction and Maintenance Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Subjects With Eosinophilic Esophagitis
INTERVENTIONAL
Inicio: 22 de feb de 2021
ID: NCT04753697
Completado
Fase 3
ClinicalTrials.gov
ING117175: a Phase IIIb, Randomized, Open-label Study of the Safety and Efficacy of Dolutegravir or Efavirenz Each Administered With Two NRTIs in HIV-1-infected Antiretroviral Therapy-naïve Adults Starting Treatment for Rifampicin-sensitive Tuberculosis
INTERVENTIONAL
Inicio: 23 de ene de 2015
ID: NCT02178592
Retirado
Fase 2
ClinicalTrials.gov
A Randomized, Multicenter, Double-Blind, Placebo Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of IgPro10 (Intravenous Immunoglobulin, Privigen®) for the Treatment of Adults With Systemic Sclerosis
INTERVENTIONAL
Inicio: 20 de dic de 2019
ID: NCT04138485
Reclutando
Fase 3
ClinicalTrials.gov
A Phase III Study to Evaluate the Efficacy of INM004 (Shiga Antitoxin) in Pediatric Patients With Shiga Toxin-producing Escherichia Coli-associated Hemolytic Uremic Syndrome.
INTERVENTIONAL
Inicio: 5 de oct de 2024
ID: NCT06389474
Reclutando
ClinicalTrials.gov
Institutional Registries of Rare Diseases at Hospital Italiano de Buenos Aires (HIBA)
OBSERVATIONAL
Inicio: 1 de jul de 2024
ID: NCT06573723
Completado
Fase 2
ClinicalTrials.gov
A Multi-center, Randomized, Double-blind, Placebo and Active-controlled Study With Exploratory Dose-ranging to Investigate the Efficacy and Safety of 16 Weeks Treatment With Subcutaneous (s.c.) QGE031 in Asthma Patients Not Adequately Controlled With High-dose Inhaled Corticosteroids and Long Acting β2-agonists
INTERVENTIONAL
Inicio: 1 de dic de 2012
ID: NCT01716754
Completado
Fase 3
ClinicalTrials.gov
A Randomized, Double-blind, Placebo Controlled Study to Evaluate Efficacy and Safety of Nefecon in Patients With Primary IgA (Immunoglobulin A) Nephropathy at Risk of Progressing to End-stage Renal Disease (NefIgArd)
INTERVENTIONAL
Inicio: 5 de sept de 2018
ID: NCT03643965
Terminado
Fase 2
ClinicalTrials.gov
A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate the Efficacy and Safety of ALXN2050 in Adult Participants With Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)
INTERVENTIONAL
Inicio: 14 de ene de 2022
ID: NCT05097989
1
2
3
4
5
6
Siguiente
Filtros